Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Neuropace, Inc. - Common Stock (NQ:NPCE)

12.46 -5.21 (-29.50%)
Streaming Delayed Price Updated: 3:50 PM EDT, May 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Neuropace, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Here are the top movers in Tuesday's session.
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Is NeuroPace Stock Falling After Epilepsy Treatment Study Data?
NeuroPace's RNS System trial showed a strong safety profile and subgroup efficacy in drug-resistant epilepsy, prompting FDA pathway discussions. 
Via Benzinga
Exposures Product Safety
Let's have a look at the top gainers and losers in the middle of the day of today's session.
Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
What 4 Analyst Ratings Have To Say About NeuroPace
Via Benzinga
Earnings Scheduled For November 12, 2024
Via Benzinga
The Latest Analyst Ratings For NeuroPace
Via Benzinga
Dow Surges Over 600 Points; US Durable Goods Orders Fall in April
Via Benzinga
Topics Stocks
Exposures US Equities
There are notable gap-ups and gap-downs in today's session.
In today's session, there are notable price gaps in the US markets on Tuesday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
Nasdaq Jumps Over 300 Points On EU Tariff Delay; AutoZone Posts Downbeat Earnings
Via Benzinga
Tower Semiconductor Posts Upbeat Earnings, Joins Nutex Health, Kornit Digital, Tencent Music Entertainment And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Recap: NeuroPace Q4 Earnings
Via Benzinga
Earnings Preview: NeuroPace
Via Benzinga
Earnings Scheduled For May 13, 2025
Via Benzinga
Kura Sushi Posts Downbeat Results, Joins Cal-Maine Foods And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
NeuroPace Announces Data From a Long-Term Post-Approval Study of the RNS System in Focal Epilepsy at the 2025 AAN Annual Meeting
From NeuroPace, Inc.
Via GlobeNewswire
NeuroPace Announces Upcoming Oral Presentation of Data from the Long-Term Post-Approval Study of the RNS System at the 2025 AAN Annual Meeting
Three-year data from NeuroPace’s Post-Approval Study of the RNS® System in drug-resistant focal epilepsy to be shared in oral presentation 
From NeuroPace, Inc.
Via GlobeNewswire
Earnings Scheduled For March 4, 2025
Via Benzinga
Acelyrin, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
MicroStrategy, Portland General Electric And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling over 100 points on Thursday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Zoomcar Shares Are Trading Higher By Around 142%; Here Are 20 Stocks Moving Premarket
Via Benzinga
NPCE Stock Earnings: NeuroPace Beats EPS, Beats Revenue for Q2 2024
NPCE stock results show that NeuroPace beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
NPCE Stock Earnings: NeuroPace Meets EPS, Beats Revenue for Q1 2024
NPCE stock results show that NeuroPace met analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
NeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024
From NeuroPace, Inc.
Via GlobeNewswire
NPCE Stock Earnings: NeuroPace Beats EPS, Beats Revenue for Q4 2023
NPCE stock results show that NeuroPace beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
NeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million
From NeuroPace, Inc.
Via GlobeNewswire
Financial Freedom Fighters: 3 Stocks to Liberate Your Portfolio
Stocks for financial freedom are generational companies that are well-run, growing fast, and focused on the future. 
Via InvestorPlace
Earnings Scheduled For March 5, 2024
Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2.29 billion. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.